Article

GPR183 mediates the capacity of the novel CD47-CD19 bispecific antibody TG-1801 to heighten ublituximab-umbralisib (U2) anti-lymphoma activity

2022-04-01

Abstract excerpt

Targeted therapies have considerably improved the survival rate of B-cell non-Hodgkin lymphoma (B-NHL) patients in the last decade; however, most subtypes remain incurable. TG-1801, a bispecific antibody that targets CD47 selectively on CD19+ B-cells, is under clinical evaluation in relapsed/refractory B-NHL patients either as a single-agent or in combination with ublituximab, a CD20 antibody, which is also being...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7ebef189-c258-576c-98ba-2c1ac8febe1a
DOI: 10.1101/2022.03.31.486558

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

GPR183 mediates the capacity of the novel CD47-CD19 bispecific antibody TG-1801 to heighten ublituximab-umbralisib (U2) anti-lymphoma activityDOI 10.1101/2022.03.31.486558Read

New targeted therapies for malignant lymphoma based on molecular heterogeneity.Semantic proximity Read

Comprehensive Analysis of <sup>177</sup> Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination SchemesSemantic proximity Read

Comprehensive Analysis of 177Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination SchemesSemantic proximity Read

A computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of actionSemantic proximity Read

CD4⁺ T-cell reserve predicts bispecific antibody efficacy and can be enhanced by BTK inhibition in B-cell lymphomaSemantic proximity Read

PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansineSemantic proximity Read

ErbB/HER family in cancer immunology: therapeutic advances and mechanismsSemantic proximity Read

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read

Non-Clinical Evaluation of the Anti-PD-1 Antibody UDIZ-007Semantic proximity Read

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.Semantic proximity Read

GPCR Inhibition in Treating LymphomaSemantic proximity Read